Four experimental Covid-19 treatments derived from the blood of recovered patients failed in testing, the drugmakers said.
The therapies from Emergent BioSolutions Inc., Grifols SA and a consortium of companies that included Takeda Pharmaceutical Co. and CSL Behring didn’t help hospitalized patients in a pivotal government-sponsored study, the drugmakers said Friday.
The failures mark a setback for the development of a class of Covid-19 treatments known as hyperimmune intravenous globulin therapies.
Doctors and researchers had high hopes the class could provide valuable new additions to the limited arsenal of Covid-19 therapies because the class had worked well against severe viral respiratory infections.
The companies announced the failure of their experimental therapies in statements, though they declined to provide more details about results.